Anzeige
Mehr »
Login
Freitag, 28.06.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
Die Ruhe vor dem Sturm... Warum Sie genau jetzt zugreifen sollten?!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
469 Leser
Artikel bewerten:
(2)

Curiteva Announces World's First 3D Printed PEEK Device With Regulatory Clearance Reaches Full Commercial Launch in the United States

The company pioneered and received clearance earlier this year on the world's first 3D printed, fully interconnected porous PEEK interbody.

HUNTSVILLE, AL / ACCESSWIRE / July 18, 2023 / Curiteva, a privately held technology and manufacturing company based in Huntsville, AL announces the commercial launch of its Inspire Porous PEEK HAFUSE Cervical Interbody System.

Curiteva, Tuesday, July 18, 2023, Press release picture

The company pioneered and received clearance earlier this year on the world's first 3D printed, fully interconnected porous PEEK interbody. This extraordinary advancement in additive manufacturing of polymers creates a new classification of interbody fusion devices with optimal characteristics for bony healing.

"We are very pleased with the positive surgeon feedback we received during our limited release in April. Now with full commercialization, the team is excited to see continued adoption of our novel 3D printed porous PEEK implant with HAFUSE Technology," stated Mark Mohlman, EVP. "This launch is just the beginning as we continue to develop our additional lumbar portfolio scheduled for launch in 2024."

The Inspire platform is manufactured with a proprietary, patented Fused Filament Fabrication 3D printer designed, programmed, and built by Curiteva. This ground-breaking additive process produces a fully interconnected and integrated porous structure traversing the entire implant to promote osseointegration, improve radiographic assessment, and deliver superior biomechanics. The first-to-market combination of the HAFUSE nanotechnology surface treatment and novel porous PEEK structure creates a hydrophilic, bioactive environment for cell attachment, proliferation, and healing in pre-clinical animal and in vitro studies.

"Curiteva received FDA clearance in February, initiated our alpha release in April and scaled to a commercial launch in July. I am proud of the entire Curiteva team for another milestone achievement and grateful to our surgeons and distributors for their patience and support," commented CEO Mike English.

The Inspire technology will be featured at the NASS meeting later this year.

Curiteva is a privately held technology and manufacturing company dedicated to advancing spine surgery and improving clinical outcomes by partnering with providers and suppliers to deliver innovative and intuitive implant systems to the market. Our business is founded on a commitment to building world-class manufacturing, accelerating research and development, maintaining lean operational discipline, and delivering novel technology to meet the evolving needs of our customers and the patients they serve.

Contact Information

Kristen Kyzer
Director of Business Development
kkyzer@curiteva.com
256.213.1057

SOURCE: Curiteva

.

View source version on accesswire.com:
https://www.accesswire.com/768660/Curiteva-Announces-Worlds-First-3D-Printed-PEEK-Device-With-Regulatory-Clearance-Reaches-Full-Commercial-Launch-in-the-United-States

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2023 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.